Ltc-2a (4-26)

General Information


DCTPep ID  DCTPep00222

Peptide Name   Ltc-2a (4-26)

Sequence  GKLIKKFGRKAISYAVKKARGKH

Sequence Length  23

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer therapy related peptides



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
K562 Blast phase chronic myelogenous leukemia, BCR-ABL6 positive; Chronic myeloid leukemia EC50>36 µM Hoechst 33342 and PI assay 3h 1

Hemolytic Activity  Human erythrocytes: 50% Hemolysis>36 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  DCTPep00222

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C119H206N38O26

Absent amino acids  CDEMNPQTW

Theoretical pI  11.33

Acidic residues  0

Basic residues  10

Polar residues  5

Molecular weight (Average)  2585.18

Molecular weight (Monoisotopic)  2583.6

Common amino acids  K

Net charge  10

Instability index (II)  0.15

Aliphatic index  76.52

Grand average of hydropathicity (GRAVY)  -0.765

Half Life 
  30 hours (mammalian reticulocytes, in vitro).
  >20 hours (yeast, in vivo).
  >10 hours (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 1490
  Abs 0.1% (=1 g/l) 0.576

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 19563807

Title  N-terminal amphipathic helix as a trigger of hemolytic activity in antimicrobial peptides: a case study in latarcins

Doi 10.1016/j.febslet.2009.06.044

Year  2009

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DCTPep is developed by Dr.Zheng's team.